Hebei develops new prescription for brain infarction

days ago, by Hebei Medical University doctoral tutor, the country's outstanding scientific and technological workers Professor Yang Muxiang, Yu Wentao, Su Fengzhe and other doctors involved in the joint development of a newtreatment of cerebral infarction- stroke Kang, passed the Hebei Province scientific and technological achievements identificationBy the domestic Chinese and Western medicine peer well-known expert sashimi, the new drug development research results up to the international levelCerebral vascular disease is a common disease and frequent morbidity in the middle and oldCerebral vascular disease deaths in urban areas are the first of all causes of death, in acute cerebrovascular disease, ischemic cerebral infarction accounted for about 50% to 70% of the total, with high disability rate, high fatality rate characteristics, currently lack of ideal treatment drugsIn view of this situation, Professor Yang Muxiang presided over the application and under the focus of theChinese Medicine
administration in Hebei Province, from theChinese medicineinternal medicine clinical and experimental aspects of the development of new drugs for the treatment of cerebral infarctionConsidering that cerebral infarction belongs to the category of "stroke disease"Chinese medicine,Chinese medicinebelieves that the occurrence of this disease is related to theofdiet, emotional injury, fatigue, positive and declining factors Its disease position in the brain and blood, the beginning of the disease in the vein, the disease gradually and the brain, the disease into the brain vein symbiosis disease, the main disease machine is liver and kidney loss, blocking the brain vein, for the false proof Professor Yang Muxiang based on many years of clinical verification, screening with the benefits of liver and kidney, sputum, sputum, and other effects of the drug group, developed into a "stroke kang" prescription The multi-center, randomized controlled clinical efficacy was observed on 259 patients with cerebral infarction, and the changes in neurofunction deficiency score, blood lipid, blood rheumatism and other indicators were detected before and after treatment, and the clinical efficacy was judged The results showed that 124 cases of stroke concomcability treatment could reduce the patient's neurological impairment score, regulate blood lipid metabolism, improve blood rheological, and the total clinical efficiency was 99.19%, which was significantly better than the control group (135 cases, with a total clinical efficiency of 82.96%) The experimental effects show that stroke can significantly improve the hypoxia state of the brain and abnormal blood rheology, and have the effect of inhibiting thrombosis Acute toxicity experiments in mice showed that stroke was not toxic It is reported that the research results in the Chinese Traditional Medicine Magazine, Traditional Chinese Medicine, China Senior Seidoc and other national publications introduced the exchange, caused a greater response in China (reproduced from China Medical Daily)